PLA2G7 and atherosclerosis: In 2014, Darapladib, developed by GlaxoSmithKline (GSK) and touted as the leading Lp‐PLA2 inhibitor in clinical trials, failed to meet the primary endpoints in two phase III trials involving patients with atherosclerosis [26, 27].